The inhibitory effects of the DPP-4 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan.

The inhibitory effects of the DPP-4 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan. - The inhibitory effects of the DPP-4 inhibitor for progression of diabetic nephropathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011101

Enrollment

Registered

2013-08-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The CKD patients with type 2 diabetes

Interventions

vildagliptin 50mg-100mg or sitagliptin 50mg-100mg or alogliptin 12.5mg-25mg or linagliptin 5mg or teneligliptin 20mg-40mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) CKD patients with type 2 diabetes * HbA1c over 6.2% 2) patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) diabetic ketoacidosis, diabetic coma, type 1 diabetes 2) with severe liver dysfunction 3) severe infection, before and after surgery, severe trauma 4) end-stage renal failure during dialysis or severe renal dysfunction (CrCl under 30ml/min) 5) pregnant 6) patients with a history of hypersensitivity to any component of this drugs

Design outcomes

Primary

Measure	Time frame
blood glucose lowering effect ; HbA1c, 1,5-AG, GA renal function ; u-L-FABP, UACR, eGFR, u-TGF-beta 1, u-Col IV	—

Secondary

Measure	Time frame
lipid profile oxidant stress blood pressure, heart rate	—

Countries

Japan

Contacts

Public ContactKoichi Kanozawa

Saitama Medical Center, Saitama Medical University Division of Nephrology and Hypertension

049-228-3604

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026